Merck, known as MSD outside the US and Canada, has acquired ophthalmic products developer Inspire Pharmaceuticals for $5 per share in cash.
Subscribe to our email newsletter
Under the acquisition, Merck‘s wholly subsidiary Monarch Transaction has merged with and into Inspire by making Inspire a wholly subsidiary of Merck.
Merck Neuroscience and Ophthalmology senior vice president and general manager Beverly Lybrand said the completion of the transaction strengthens their ophthalmology business and positions the company for future growth with an expanded portfolio and a best in class commercialization organization.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.